Related Experiment Video
Updated: Mar 6, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
Glucagon-like peptide-1 receptor agonists in rheumatoid arthritis
Ryan Massay1, Angela Malani, Aaron Stubbs
1Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Purpose Of Review:
This article synthesizes current preclinical and clinical literature regarding glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in rheumatoid arthritis (RA), highlights mechanistic hypotheses and explores potential clinical roles and limitations of their use.
Recent Findings:
GLP-1 RAs are established therapies for type 2 diabetes mellitus and obesity, with demonstrated benefits on glycemic control and cardiovascular risk reduction. Emerging evidence suggests that GLP-1 RAs may exert anti-inflammatory and immunomodulatory effects relevant to RA.
Summary:
Present evidence is insufficient to recommend GLP-1 RAs as standard RA therapy. Well designed randomized controlled trials are needed to establish their efficacy and optimal role.
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Dipeptidyl Peptidase 4 Inhibitors
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Oral Hypoglycemic Agents: Glinides
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...

